Picture [LSA] – The Business Web Portal 650x89px
Product › Details

RNArt® technology

Products Next higher product group RNA technology
Period Status 2015-11-03 development existent
Organisation Organisation CureVac GmbH
  Today CureVac AG

Evotec AG. (10/5/15). "Press Release: Evotec Awarded Multi-year Contract to Manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center". Hamburg.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute (“NCI”), Department of Health and Human Services. Under the terms of the agreement, Evotec will provide compound management services to the NCI Chemical Biology Consortium (“CBC”) for a period of five years with a total estimated value of up to € 4.5 m ($ 4.9 m).

The NCI Chemical Biology Consortium contract will continue to provide to acquire, store, maintain and distribute the current library collection. This repository will form part of the CBC’s drug discovery and development platform for new oncology therapeutics being researched by a consortium of primarily academic and non-profit institutions.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are pleased the NCI has elected to award Evotec this important contract to support the Chemical Biology Consortium, an important initiative in the discovery of new cancer treatments.“


The NCI Chemical Biology Consortium (“CBC”) was established in 2009 to facilitate the discovery and development of new agents to treat cancer. The Consortium brings together chemical biologists and molecular oncologists from government, industry and academia to address unmet needs in therapeutic oncology. Through the CBC and the interactions among the various participants, the NCI’s drug discovery and development pipeline now spans from target identification through proof-of-concept clinical trials. The project is funded in whole with U.S. Federal funds from the National Institutes of Health, Department of Health and Human Services, under contract HHSN261201500010I with Evotec (US), Inc.


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease. For additional information please go to

FORWARD LOOKING STATEMENTS — Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Record changed: 2018-01-15


Picture [LSA] – The Business Web Portal 650x89px

More documents for RNA technology

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSA] – The Business Web Portal 650x89px

» top